Flow Cytometry Application Service in CAR-T System

Navigating the complexities of CAR-T cell therapy development is challenging, especially when it comes to monitoring CAR-T cell kinetics, ensuring sample stability, and standardizing data across multi-site clinical trials. Creative Biolabs' Flow Cytometry Application in CAR-T System offers a solution to these hurdles. Our advanced multiparametric flow cytometry platforms are designed to streamline and accelerate your research by providing robust, reproducible data. This allows you to focus on the core scientific questions, moving your CAR-T therapy development forward with greater confidence and efficiency.

Introduction

Flow cytometry, a laser-based optical technology, enables high-speed, multiparametric quantification and sorting of individual cells in suspension. In the discovery and clinical validation of CAR-T therapies, it has become indispensable: from phenotypic profiling and functional assessment of CAR-T cells, including activation status, exhaustion markers, and cytokine secretion, to longitudinal monitoring of in vivo and ex vivo cell kinetics and global immune status throughout treatment. By standardizing quality control of CAR-T products and furnishing robust biomarkers of therapeutic response and durability, flow cytometry has markedly enhanced the controllability and safety of CAR-T immunotherapy.

Fig.1 Application of advanced flow cytometry in CAR-T cell therapy monitoring.¹

Flow Cytometry Application in CAR-T System at Creative Biolabs

Creative Biolabs' Flow Cytometry Application in CAR-T System provides a fully integrated portfolio of flow-cytometry services engineered exclusively for CAR-T cell discovery and patient-tailored surveillance. Leveraging ultra-high-sensitivity, dual-parameter-optimized panels, we enumerate CAR-T cells, resolve their phenotypic landscape, and map their longitudinal persistence and biodistribution in vivo, delivering the quantitative, decision-grade data required to advance programs from bench to bedside with confidence.

What we can offer

Creative Biolabs integrates a comprehensive suite of flow cytometry platforms throughout the entire CAR-T therapy development pipeline from preclinical candidate screening to clinical-phase patient monitoring. This systematic application ensures rigorous quality control, guaranteeing that the final cellular product is characterized by high viability and desired biological function.

Our Service Process

We ensure a streamlined and collaborative experience in applying flow cytometry to your CAR-T projects. Through proactive communication and meticulous attention to detail, our process translates your specific requirements into actionable, high-fidelity data, de-risking your path to critical milestones.

Required Starting Materials:

• Patient peripheral blood mononuclear cells (PBMCs) or other relevant tissue samples.
• Detailed information on the CAR construct.
• A list of desired phenotyping markers.

Key Steps Involved:

Final Deliverables:

• Raw data files.
• A detailed final report including analyzed data and key findings.

Key Advantages

• Comprehensive and End-to-End Service: We deliver a fully integrated workflow for flow cytometry-based CAR-T cell analysis, encompassing initial experimental design, robust assay execution, through to in-depth data interpretation and structured reporting.
• Tailored Assay Development: Our team collaborates directly with you to develop and optimize customized staining panels, ensuring precise detection and characterization of your specific CAR construct and associated antigen targets for highly relevant research outcomes.
• High-Sensitivity Detection Reagents: Utilizing our proprietary, high-performance reagents, we enable exceptional assay sensitivity with exceptionally low background, capable of identifying rare CAR-T cell populations.

FAQ

Why Choose Us?

As a premier expert in antibody discovery and immunotherapy, Creative Biolabs offers comprehensive, end-to-end solutions for CAR-T therapy development. Flow cytometry serves as an indispensable laser-driven analytical tool for evaluating CAR-T cell properties, spanning applications from biomarker detection to clinical-stage validation. Based on our integrated CAR-T service platform, Creative Biolabs provides a full suite of flow cytometry instruments and reagents designed to ensure precise and reliable outcomes.

Customer Reviews

"The application of Creative Biolabs' flow cytometry solutions has been instrumental in achieving profound phenotypic characterization of our CAR-T cells. The exceptional sensitivity of their detection reagents enabled us to accurately quantify even minimal populations of circulating CAR-T cells, a critical factor for assessing patient-specific therapeutic responses." D. J***son, Principal Scientist.

"Creative Biolabs' services delivered the level of precision required for our clinical-stage work. The high degree of correlation established between their flow cytometry analyses and our orthogonal qPCR data provided strong validation, allowing us to confidently adopt their more efficient platform for routine monitoring." M. M***ler, Clinical Research Manager.

"The operational expertise from Creative Biolabs was transformative. They collaborated with us to optimize a sample-handling protocol that effectively mitigated stability concerns during inter-facility transportation, thereby safeguarding data integrity and avoiding significant project delays." A. G***a, Lab Director.

How to contact us?

Our consortium of specialists is prepared to collaboratively engage with your team to design and implement a customized strategy, precisely aligned with your unique project requirements. We welcome you to initiate a conversation with us to facilitate an in-depth discussion.

Leverage Our Expertise – Discuss Your Project and Receive a Quote

Reference

1. Blache, Ulrich et al. "Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications." Frontiers in immunology vol. 12 658314. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2021.658314.